RU2470639C2 - Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид - Google Patents
Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид Download PDFInfo
- Publication number
- RU2470639C2 RU2470639C2 RU2010120806/15A RU2010120806A RU2470639C2 RU 2470639 C2 RU2470639 C2 RU 2470639C2 RU 2010120806/15 A RU2010120806/15 A RU 2010120806/15A RU 2010120806 A RU2010120806 A RU 2010120806A RU 2470639 C2 RU2470639 C2 RU 2470639C2
- Authority
- RU
- Russia
- Prior art keywords
- drug
- acid
- mixture
- mass
- dose
- Prior art date
Links
- 239000002253 acid Substances 0.000 title claims abstract description 62
- 239000000203 mixture Substances 0.000 title description 177
- 239000003246 corticosteroid Substances 0.000 title description 12
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 title description 6
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 title description 6
- 239000003814 drug Substances 0.000 claims abstract description 120
- 229940079593 drug Drugs 0.000 claims abstract description 106
- 229960005127 montelukast Drugs 0.000 claims description 64
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims description 58
- 229960002744 mometasone furoate Drugs 0.000 claims description 25
- WOFMFGQZHJDGCX-ZULDAHANSA-N mometasone furoate Chemical compound O([C@]1([C@@]2(C)C[C@H](O)[C@]3(Cl)[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2C[C@H]1C)C(=O)CCl)C(=O)C1=CC=CO1 WOFMFGQZHJDGCX-ZULDAHANSA-N 0.000 claims description 25
- 208000006673 asthma Diseases 0.000 claims description 11
- 229940112141 dry powder inhaler Drugs 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 210000002345 respiratory system Anatomy 0.000 claims description 6
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 229940071648 metered dose inhaler Drugs 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 15
- 208000023504 respiratory system disease Diseases 0.000 abstract description 4
- 230000000694 effects Effects 0.000 abstract description 3
- 239000000126 substance Substances 0.000 abstract description 3
- 229960001664 mometasone Drugs 0.000 abstract description 2
- QLIIKPVHVRXHRI-CXSFZGCWSA-N mometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CCl)(O)[C@@]1(C)C[C@@H]2O QLIIKPVHVRXHRI-CXSFZGCWSA-N 0.000 abstract description 2
- 239000002245 particle Substances 0.000 description 70
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 69
- 239000008101 lactose Substances 0.000 description 69
- 239000002775 capsule Substances 0.000 description 63
- 238000009472 formulation Methods 0.000 description 61
- 238000002347 injection Methods 0.000 description 34
- 239000007924 injection Substances 0.000 description 34
- 150000001875 compounds Chemical class 0.000 description 33
- 239000013543 active substance Substances 0.000 description 26
- 238000009826 distribution Methods 0.000 description 25
- 239000010419 fine particle Substances 0.000 description 25
- 239000000843 powder Substances 0.000 description 25
- 238000000227 grinding Methods 0.000 description 22
- 239000008186 active pharmaceutical agent Substances 0.000 description 20
- 238000000034 method Methods 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 238000011068 loading method Methods 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000002904 solvent Substances 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 238000000338 in vitro Methods 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 239000006185 dispersion Substances 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 239000000443 aerosol Substances 0.000 description 6
- 230000008021 deposition Effects 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 239000003380 propellant Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 5
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000011521 glass Substances 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 235000005772 leucine Nutrition 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000004570 mortar (masonry) Substances 0.000 description 5
- 241001494479 Pecora Species 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000003993 interaction Effects 0.000 description 4
- 238000000634 powder X-ray diffraction Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 239000003470 adrenal cortex hormone Substances 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 description 2
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 229940125388 beta agonist Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 239000008121 dextrose Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000004519 grease Substances 0.000 description 2
- 150000005828 hydrofluoroalkanes Chemical class 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 229960001951 montelukast sodium Drugs 0.000 description 2
- LBFBRXGCXUHRJY-HKHDRNBDSA-M montelukast sodium Chemical compound [Na+].CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC([O-])=O)CC1 LBFBRXGCXUHRJY-HKHDRNBDSA-M 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 229920001296 polysiloxane Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 208000005069 pulmonary fibrosis Diseases 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000001878 scanning electron micrograph Methods 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- UFCOHPJEZNHBRJ-UHFFFAOYSA-N 4-oxo-3h-1,8-naphthyridine-3-carboxamide Chemical compound C1=CC=C2C(=O)C(C(=O)N)C=NC2=N1 UFCOHPJEZNHBRJ-UHFFFAOYSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- VOVIALXJUBGFJZ-KWVAZRHASA-N Budesonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(CCC)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O VOVIALXJUBGFJZ-KWVAZRHASA-N 0.000 description 1
- PJFHZKIDENOSJB-UHFFFAOYSA-N Budesonide/formoterol Chemical compound C1=CC(OC)=CC=C1CC(C)NCC(O)C1=CC=C(O)C(NC=O)=C1.C1CC2=CC(=O)C=CC2(C)C2C1C1CC3OC(CCC)OC3(C(=O)CO)C1(C)CC2O PJFHZKIDENOSJB-UHFFFAOYSA-N 0.000 description 1
- LUKZNWIVRBCLON-GXOBDPJESA-N Ciclesonide Chemical compound C1([C@H]2O[C@@]3([C@H](O2)C[C@@H]2[C@@]3(C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]32)C)C(=O)COC(=O)C(C)C)CCCCC1 LUKZNWIVRBCLON-GXOBDPJESA-N 0.000 description 1
- 229940098777 Corticosteroid agonist Drugs 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000102542 Kara Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000244206 Nematoda Species 0.000 description 1
- 206010062701 Nematodiasis Diseases 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 239000001744 Sodium fumarate Substances 0.000 description 1
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
- YYAZJTUGSQOFHG-IAVNQIGZSA-N [(6s,8s,10s,11s,13s,14s,16r,17r)-6,9-difluoro-17-(fluoromethylsulfanylcarbonyl)-11-hydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate;2-(hydroxymethyl)-4-[1-hydroxy-2-[6-(4-phenylbutoxy)hexylamino]eth Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)C1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O YYAZJTUGSQOFHG-IAVNQIGZSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940090167 advair Drugs 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 229940099032 alvesco Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 201000009361 ascariasis Diseases 0.000 description 1
- 229940053670 asmanex Drugs 0.000 description 1
- 229940092705 beclomethasone Drugs 0.000 description 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 229960004436 budesonide Drugs 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 208000023819 chronic asthma Diseases 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- MSJMDZAOKORVFC-SEPHDYHBSA-L disodium fumarate Chemical compound [Na+].[Na+].[O-]C(=O)\C=C\C([O-])=O MSJMDZAOKORVFC-SEPHDYHBSA-L 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 229960000676 flunisolide Drugs 0.000 description 1
- 229960000289 fluticasone propionate Drugs 0.000 description 1
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 229940125369 inhaled corticosteroids Drugs 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000003801 milling Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000000399 optical microscopy Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- MNDBXUUTURYVHR-UHFFFAOYSA-N roflumilast Chemical compound FC(F)OC1=CC=C(C(=O)NC=2C(=CN=CC=2Cl)Cl)C=C1OCC1CC1 MNDBXUUTURYVHR-UHFFFAOYSA-N 0.000 description 1
- 229960002586 roflumilast Drugs 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940005573 sodium fumarate Drugs 0.000 description 1
- 235000019294 sodium fumarate Nutrition 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 229940035073 symbicort Drugs 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32707P | 2007-10-25 | 2007-10-25 | |
| US61/000,327 | 2007-10-25 | ||
| PCT/CA2008/001874 WO2009052624A1 (en) | 2007-10-25 | 2008-10-23 | Combination therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2010120806A RU2010120806A (ru) | 2011-11-27 |
| RU2470639C2 true RU2470639C2 (ru) | 2012-12-27 |
Family
ID=40579006
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2010120806/15A RU2470639C2 (ru) | 2007-10-25 | 2008-10-23 | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100210611A1 (enExample) |
| EP (1) | EP2211863A4 (enExample) |
| JP (1) | JP2011500731A (enExample) |
| KR (1) | KR20100072295A (enExample) |
| CN (1) | CN101909626A (enExample) |
| AU (1) | AU2008316283A1 (enExample) |
| CA (1) | CA2701956A1 (enExample) |
| CO (1) | CO6270213A2 (enExample) |
| CR (1) | CR11439A (enExample) |
| DO (1) | DOP2010000122A (enExample) |
| GT (1) | GT201000107A (enExample) |
| IL (1) | IL205182A0 (enExample) |
| MA (1) | MA33705B1 (enExample) |
| MX (1) | MX2010004529A (enExample) |
| NI (1) | NI201000069A (enExample) |
| NZ (1) | NZ584876A (enExample) |
| RU (1) | RU2470639C2 (enExample) |
| WO (1) | WO2009052624A1 (enExample) |
| ZA (1) | ZA201002562B (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2012168907A1 (en) | 2011-06-10 | 2012-12-13 | Glenmark Pharmaceuticals Sa | Pharmaceutical composition comprising revamilast and montelukast or zafirlukast |
| WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
| JP2017503814A (ja) | 2014-01-22 | 2017-02-02 | タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ | 部分的コントロール状態の重症喘息またはコントロール不良状態の重症喘息のｐｄｅ４インヒビターを用いた（およびロイコトリエン調節薬と組み合わせて用いた）治療 |
| CN108267531B (zh) * | 2016-12-31 | 2022-01-11 | 天津金耀集团有限公司 | 一种环索奈德有关物质hplc测定方法 |
| IT201900014178A1 (it) * | 2019-08-06 | 2021-02-06 | Genetic S P A | Esteri del montelukast e loro formulazioni farmaceutiche |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024488A2 (en) * | 2001-09-19 | 2003-03-27 | Altana Pharma Ag | Combination of a pde inhibitor and a leukotriene receptor antagonist |
| WO2005025578A1 (en) * | 2003-09-16 | 2005-03-24 | Altana Pharma Ag | Use of ciclesonide for the treatment of respiratory diseases |
| WO2005074982A2 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| RU2005107475A (ru) * | 2002-08-17 | 2006-04-10 | Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De) | Ингаляционные лекарственные средства, содержащие новое антихолинергическое средство в сочетании с кортикостероидами и бетамиметиками |
| WO2006097250A1 (en) * | 2005-03-16 | 2006-09-21 | Meda Pharma Gmbh & Co Kg | The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases |
| WO2006099591A1 (en) * | 2005-03-16 | 2006-09-21 | Elan Pharma International Limited | Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5837699A (en) * | 1994-01-27 | 1998-11-17 | Schering Corporation | Use of mometasone furoate for treating upper airway passage diseases |
| US20040214805A1 (en) * | 1999-11-02 | 2004-10-28 | Smithkline Beecham Corporation | Method and compositions for treating pulmonary diseases |
| CA2427814C (en) * | 2000-11-07 | 2009-06-02 | Merck & Co., Inc. | A combination of a pde4 inhibitor and a leukotriene antagonist in the treatment of bronchial and respiratory disorders |
| JO2311B1 (en) * | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| US7550133B2 (en) * | 2002-11-26 | 2009-06-23 | Alexza Pharmaceuticals, Inc. | Respiratory drug condensation aerosols and methods of making and using them |
| AU2004283832B2 (en) * | 2003-10-10 | 2011-04-07 | Synthon B.V. | Solid-state montelukast |
| EP1616567A1 (en) * | 2004-07-16 | 2006-01-18 | Boehringer Ingelheim Pharma GmbH & Co.KG | Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts |
| WO2007036029A1 (en) * | 2005-09-28 | 2007-04-05 | Merck Frosst Canada Ltd. | Aerosol powder formulation comprising sieved lactose |
-
2008
- 2008-10-23 RU RU2010120806/15A patent/RU2470639C2/ru not_active IP Right Cessation
- 2008-10-23 NZ NZ584876A patent/NZ584876A/en not_active IP Right Cessation
- 2008-10-23 CN CN2008801225895A patent/CN101909626A/zh active Pending
- 2008-10-23 MX MX2010004529A patent/MX2010004529A/es not_active Application Discontinuation
- 2008-10-23 AU AU2008316283A patent/AU2008316283A1/en not_active Abandoned
- 2008-10-23 KR KR1020107009041A patent/KR20100072295A/ko not_active Withdrawn
- 2008-10-23 EP EP08842623A patent/EP2211863A4/en not_active Withdrawn
- 2008-10-23 JP JP2010530233A patent/JP2011500731A/ja active Pending
- 2008-10-23 US US12/738,946 patent/US20100210611A1/en not_active Abandoned
- 2008-10-23 CA CA2701956A patent/CA2701956A1/en not_active Abandoned
- 2008-10-23 WO PCT/CA2008/001874 patent/WO2009052624A1/en not_active Ceased
-
2010
- 2010-04-13 ZA ZA2010/02562A patent/ZA201002562B/en unknown
- 2010-04-18 IL IL205182A patent/IL205182A0/en unknown
- 2010-04-19 GT GT201000107A patent/GT201000107A/es unknown
- 2010-04-22 NI NI201000069A patent/NI201000069A/es unknown
- 2010-04-22 CO CO10047531A patent/CO6270213A2/es not_active Application Discontinuation
- 2010-04-23 DO DO2010000122A patent/DOP2010000122A/es unknown
- 2010-05-18 CR CR11439A patent/CR11439A/es not_active Application Discontinuation
- 2010-05-20 MA MA32860A patent/MA33705B1/fr unknown
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003024488A2 (en) * | 2001-09-19 | 2003-03-27 | Altana Pharma Ag | Combination of a pde inhibitor and a leukotriene receptor antagonist |
| RU2005107475A (ru) * | 2002-08-17 | 2006-04-10 | Берингер Ингельхайм Фарма Гмбх Унд Ко.Кг (De) | Ингаляционные лекарственные средства, содержащие новое антихолинергическое средство в сочетании с кортикостероидами и бетамиметиками |
| WO2005025578A1 (en) * | 2003-09-16 | 2005-03-24 | Altana Pharma Ag | Use of ciclesonide for the treatment of respiratory diseases |
| WO2005074982A2 (en) * | 2004-02-06 | 2005-08-18 | Meda Pharma Gmbh & Co. Kg | Combination of anticholinergics and inhibitors of phosphodiesterase type 4 for the treatment of respiratory diseases |
| WO2006097250A1 (en) * | 2005-03-16 | 2006-09-21 | Meda Pharma Gmbh & Co Kg | The combination of anticholinergics and leukotriene recptor antagonists for the treatment of repiratory diseases |
| WO2006099591A1 (en) * | 2005-03-16 | 2006-09-21 | Elan Pharma International Limited | Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2011500731A (ja) | 2011-01-06 |
| EP2211863A4 (en) | 2012-07-25 |
| CA2701956A1 (en) | 2009-04-30 |
| RU2010120806A (ru) | 2011-11-27 |
| NZ584876A (en) | 2012-06-29 |
| GT201000107A (es) | 2012-03-13 |
| MA33705B1 (fr) | 2012-11-01 |
| US20100210611A1 (en) | 2010-08-19 |
| ZA201002562B (en) | 2011-06-29 |
| CN101909626A (zh) | 2010-12-08 |
| IL205182A0 (en) | 2010-11-30 |
| AU2008316283A1 (en) | 2009-04-30 |
| WO2009052624A1 (en) | 2009-04-30 |
| WO2009052624A9 (en) | 2010-11-25 |
| DOP2010000122A (es) | 2010-07-15 |
| EP2211863A1 (en) | 2010-08-04 |
| CO6270213A2 (es) | 2011-04-20 |
| CR11439A (es) | 2010-06-21 |
| NI201000069A (es) | 2010-08-23 |
| KR20100072295A (ko) | 2010-06-30 |
| MX2010004529A (es) | 2010-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8512753B2 (en) | Micronized particles of low-dosage strength active agents for powder formulations for inhalation | |
| RU2666963C2 (ru) | Агрегированные частицы | |
| CA2871358C (en) | Novel dosage form and formulation of abediterol | |
| JP2015519394A (ja) | キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法 | |
| RU2470639C2 (ru) | Композиции для ингаляции, содержащие кислоту монтелукаст и ингибитор pde-4 или ингаляционный кортикостероид | |
| US20120101077A1 (en) | Agglomerate formulations useful in dry powder inhalers | |
| CN105338967A (zh) | 包含布地奈德和福莫特罗的药物组合物 | |
| AU2021200396B2 (en) | Pharmaceutical composition containing budesonide and formoterol | |
| RU2823554C1 (ru) | Новые частицы носителя для сухих порошковых составов для ингаляции | |
| KR102898819B1 (ko) | 흡입용 건조 분말 제제를 위한 신규 담체 입자 | |
| US20120097160A1 (en) | Agglomerate formulations including active pharmaceutical agents with targeted particle sizes | |
| HK40064779A (en) | Novel carrier particles for dry powder formulations for inhalation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20131024 |